Elsevier

Gynecologic Oncology

Volume 72, Issue 2, February 1999, Pages 199-201
Gynecologic Oncology

Regular Article
Prediction of Recurrent and Residual Cervical Dysplasia by Human Papillomavirus Detection among Patients with Abnormal Cytology

https://doi.org/10.1006/gyno.1998.5250Get rights and content

Abstract

To determine the discriminative capacity of human papillomavirus (HPV) DNA testing for recurrent and residual cervical dysplasia, 43 patients with abnormal cytology after treatment for cervical dysplasia were tested for the presence of HPV DNA by PCR. An endocervical curettage was performed in all patients for histological examination. Sixteen of the 43 patients showed moderate or severe dysplasia. The HPV test was positive in all 16 patients with recurrent or residual dysplasia and negative in 12 of the 27 patients without dysplasia. The sensitivity and specificity of the HPV test were 100 and 44%, respectively. The likelihood ratio of a positive HPV test was 1.8, whereas a negative HPV test had a likelihood ratio of 0.12. Testing for the presence of HPV has the potential to select patients without recurrent or residual cervical dysplasia who have an abnormal cytological smear. This may have clinical implications, since unnecessary diagnostic conizations may be avoided in patients with abnormal cytology after treatment for cervical dysplasia and a negative HPV test.

References (18)

There are more references available in the full text version of this article.

Cited by (79)

  • Study of high-risk hpv infection clearance after conization

    2021, Clinica e Investigacion en Ginecologia y Obstetricia
  • Value of endocervical margin and high-risk human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and microinvasive carcinoma of the uterine cervix

    2014, Gynecologic Oncology
    Citation Excerpt :

    Colposcopy with directed biopsy has been shown to miss residual/recurrent lesions [3]. In addition, the Papanicolaou (Pap) test has some inherent flaws due to its relatively high rate of false negativity and low sensitivity after the conization [4,5]. Therefore, annual cervical cytology accompanied by human papillomavirus (HPV) testing at 12 and 24 months has been recently used to monitor for women treated for high-grade CIN because high-risk (HR)-HPV assessment is beneficial in identifying the undetected high-grade residual/recurrent disease [6].

  • Follow-up after LLETZ: A study of 682 cases of CIN 2-CIN 3 in a single institution

    2012, European Journal of Obstetrics and Gynecology and Reproductive Biology
    Citation Excerpt :

    In our study, we found no significant difference with respect to age between patients with normal follow-up and those who had a recurrent or persistent lesion. Numerous studies have shown that there is a highly significant association between persistent infection with HR-HPV and persistent or recurrent disease [13,18,22]. In our work, the HPV testing was made initially with PCR but since 2003, our laboratory has used the HC II test routinely.

  • Predictors of recurrence in high-grade cervical lesions and a plan of management

    2010, European Journal of Surgical Oncology
    Citation Excerpt :

    An indicator that predicts successful outcome thus allowing to minimize the follow-up period would be particularly helpful. Several authors suggest follow-up after treatment should combine the HR-HPV test with the smear as it identifies patients with high risk of recurrence.4,12,29 We suggest HPV test after treatment would be useful when surgical margins are positive because even if the PNV is not much improved (respectively 90.8% and 97%), PPV is improved by 70% (respectively 31.2% and 100%).

View all citing articles on Scopus
1

To whom correspondence and reprint requests should be addressed at the Department of Virology, Academic Medical Center, Building L1, Room 158, Meibergdreef 15, 1105 A2 Amsterdam, The Netherlands. Fax: 31206979271.

View full text